An important number of studies have shown a clear increase in AD neuropathology (amyloid deposits and tau pathology, as well as alterations of the brain vasculature) when diabetogenic interventions are conducted [32,439,454]. The gene discussed is MAPT; the disease is Alzheimer disease.